158 related articles for article (PubMed ID: 7915909)
1. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Nicoletti MI; Lucchini V; Massazza G; Abbott BJ; D'Incalci M; Giavazzi R
Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.
Massazza G; Tomasoni A; Lucchini V; Allavena P; Erba E; Colombo N; Mantovani A; D'Incalci M; Mangioni C; Giavazzi R
Int J Cancer; 1989 Sep; 44(3):494-500. PubMed ID: 2777413
[TBL] [Abstract][Full Text] [Related]
4. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Dykes DJ; Bissery MC; Harrison SD; Waud WR
Invest New Drugs; 1995; 13(1):1-11. PubMed ID: 7499102
[TBL] [Abstract][Full Text] [Related]
5. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
[TBL] [Abstract][Full Text] [Related]
6. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Tanaka M; Obata T; Sasaki T
Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
[TBL] [Abstract][Full Text] [Related]
9. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
[TBL] [Abstract][Full Text] [Related]
11. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Verschraegen CF; Sittisomwong T; Kudelka AP; Guedes Ed; Steger M; Nelson-Taylor T; Vincent M; Rogers R; Atkinson EN; Kavanagh JJ
J Clin Oncol; 2000 Jul; 18(14):2733-9. PubMed ID: 10894873
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
14. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
[TBL] [Abstract][Full Text] [Related]
15. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; Kegel A; Welters MJ
Cancer Lett; 1994 Jun; 81(2):151-4. PubMed ID: 7912164
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
17. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in the treatment of ovarian cancer.
Kavanagh JJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Shakuto S; Fujita F; Fujita M
Gan To Kagaku Ryoho; 2006 Mar; 33(3):337-43. PubMed ID: 16531714
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
